在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。
// In a loop, this can exhaust connection pools
。关于这个话题，谷歌浏览器【最新下载地址】提供了深入分析
Москвичей предупредили о резком похолодании09:45
const res = new Array(n).fill(0);
By signing up, you agree to receive recurring automated SMS marketing messages from Mashable Deals at the number provided. Msg and data rates may apply. Up to 2 messages/day. Reply STOP to opt out, HELP for help. Consent is not a condition of purchase. See our Privacy Policy and Terms of Use.